Oxford University Hospitals NHS Foundation Trust activated as ReNeuron’s first UK study site
18 October 2021: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides a further update on the progress of its Phase 2a clinical evaluations for the treatment of retinitis pigmentosa (‘RP’), an inherited, degenerative eye disease.
18 October 2021: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides an update on changes to the Company’s Board of Directors.
Significantly improved delivery of functional proteins to the brain demonstrated in vivo
Exosomes have potential to transform effective drug delivery for key neurological diseases
11 October 2021: ReNeuron Group plc (AIM: RENE), a global leader in the development of exosome therapeutics, announces positive data that provides clear pre-clinical proof-of-concept that ReNeuron’s novel exosome drug delivery technology can effectively deliver therapeutic proteins to the specific region of the brain affected by several neurological diseases.
01 October 2021: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides an update on the Company’s Phase 2a clinical evaluations for the treatment of retinitis pigmentosa (‘RP’), an inherited, degenerative eye disease.
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that at the Annual General Meeting (AGM) held earlier today, all resolutions were duly passed.
06 August 2021: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces the appointment of Catherine Isted, ACMA, who will be joining the Board as Chief Financial Officer effective 11 October 2021.
14 July 2021: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that Barbara Staehelin has joined the Board as senior independent Non-Executive Director with immediate effect.
08 July 2021: ReNeuron Group plc (AIM: RENE.L), a UK-based global leader in the development of cell-based therapeutics, announces its preliminary results for the year ended 31 March 2021.
02 July 2021: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, will announce its preliminary results for the year ended 31 March 2021 on Thursday 8 July 2021.
01 July 2021: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces today that Iain Ross has joined as a Non-Executive Director and Chairman of the Board of Directors with immediate effect. Dr. Tim Corn is stepping down as Chairman of the Board of Directors, but will remain as a Non-Executive Director.
